Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Fastenal shares rise after Jefferies raises target price

BUZZ - Fastenal shares rise after Jefferies raises target price

路透社路透社2026/10/12 15:26
Show original

- ** Industrial supplies distributor Fastenal (FAST.O) shares rose 2%, closing at $51.73

** Jefferies raised its target price for FAST from $52 to $60, leaving an 18% upside from the last closing price; maintained "Buy" rating

** The institution said investors favor distributors focused on industrial customers, while enterprises focusing on the residential market have seen declines in value

** Ongoing growth in the industrial sector is expected to drive up Fastenal's valuation

** Highlighted that manufacturing demand is expanding, Fastenal's nearly all end markets achieved double-digit growth, and as regional competitors struggle to match its supply chain coverage, the company's market share continues to increase

** Out of 21 brokerages, 6 rate the stock as “Buy” or above, 10 rate it “Hold,” and 5 rate it “Sell” or below; the median target price is $48—data compiled by LSEG

** Including the day's price movement, the stock has gained 28.7% year-to-date


(To facilitate non-native English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of this translated text. This translation is provided for readers’ convenience only. Reuters assumes no responsibility for any damage or loss resulting from the use of this translated content.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56

Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go

Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.

智通财经•2026/10/13 01:36